STAT3 and hepatocellular carcinoma: TLR9 overactivation can enhance the therapeutical efficacy of PD-1 or PD-L1 on HCC treatment by promoting PD-L1 transcription and enhancing the phosphorylation of STAT3 Tyr705 (72).